Paper
The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.
Published Dec 15, 2006 · S. Bour, M. Iglesias-Osma, L. Marti
European journal of pharmacology
Q1 SJR score
26
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Non-RCT
Animal Study
Rigorous JournalStudy Snapshot
BU 224 and 2-BFI inhibit MAO-A and -B activities, hydrogen peroxide production, and lipolysis in adipocytes, with unique effects on white adipose tissue compared to their effects on brain or endocrine pancreas.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X
Imidazoline antihypertensive agents, such as moxonidine and rilmenidine, rapidly reduce plasma triglyceride and cholesterol levels in metabolic syndrome X rats, with the main site of action likely within the liver to reduce triglyceride synthesis and secretion.
2006·24citations·Rodney A Velliquette et al.·Naunyn-Schmiedeberg's Archives of Pharmacology
Naunyn-Schmiedeberg's Archives of Pharmacology
Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism.
Methylamine shows potential anti-hyperglycemic properties, while mafenide shows no insulin-mimicking effects in human adipocytes.
2005·29citations·M. Iglesias-Osma et al.·Pharmacological research
Pharmacological research
Specific Inhibition of Hormone-Sensitive Lipase Improves Lipid Profile while Reducing Plasma Glucose
Inhibiting hormone-sensitive lipase improves insulin sensitivity and blood glucose handling in type 2 diabetes by decreasing plasma fatty acids and glycerol levels.
2005·87citations·T. Claus et al.·Journal of Pharmacology and Experimental Therapeutics
Journal of Pharmacology and Experimental Therapeutics
Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide.
Tyramine improves glucose disposal in diabetic rats, while amine oxidase inhibition does not, suggesting that activation may be more beneficial for diabetes management than inhibition.
2005·29citations·V. Visentin et al.·European journal of pharmacology
European journal of pharmacology
Characterisation of imidazoline I2 binding sites in pig brain.
Pig brain contains imidazoline I2 binding sites, with pharmacology similar to other species, and the pig may provide a more useful model for human imidazoline I2 binding sites than other species like the rat.
2005·13citations·N. Anderson et al.·European journal of pharmacology
European journal of pharmacology
Citations
Multiple Direct Effects of the Dietary Protoalkaloid N-Methyltyramine in Human Adipocytes
N-methyltyramine (NMT) has multiple effects on human adipocytes, making it a complex agent that may not improve lipid mobilization and fat oxidation in consumers of NMT-containing dietary supplements.
2022·1citation·C. Carpéné et al.·Nutrients
Nutrients
Increased monoamine oxidase activity and imidazoline binding sites in insulin-resistant adipocytes from obese Zucker rats
Insulin-resistant adipocytes in obese Zucker rats exhibit increased MAO activity and imidazoline binding sites, but tyramine's glucose transport stimulation is decreased as much as insulin's in these cells.
2022·2citations·C. Carpéné et al.·World Journal of Biological Chemistry
World Journal of Biological Chemistry
High doses of tyramine stimulate glucose transport in human fat cells
High doses of tyramine partially mimic insulin's effect on glucose uptake in human fat cells, suggesting other MAO substrates may modulate carbohydrate metabolism.
2022·7citations·C. Carpéné et al.·Journal of Physiology and Biochemistry
Journal of Physiology and Biochemistry
Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO
Inhibiting SSAO activity, such as caffeine, may help reduce weight gain and prevent obesity-related diseases.
2020·17citations·Dimitri Papukashvili et al.·Nutrients
Nutrients
Effects of imidazoline I2 receptor agonists on reserpine-induced hyperalgesia and depressive-like behavior in rats
I2R agonists show potential in treating fibromyalgia-related pain and comorbid depression by reducing immobility time in rats.
2019·11citations·Justin N Siemian et al.·Behavioural Pharmacology
Behavioural Pharmacology
A novel selective MAO‐B inhibitor with neuroprotective and anti‐Parkinsonian properties
DBZIM is a promising neuroprotectant for Parkinson's disease with anti-MAO-B properties, providing greater anti-parkinsonian and neuroprotective effects than l-deprenyl.
2018·17citations·Hugh H. N. Chan et al.·European Journal of Pharmacology
European Journal of Pharmacology
Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.
Piceatannol and resveratrol both inhibit fat cell lipogenic activity, but piceatannol has a stronger antilipolytic effect, potentially limiting obesity-related lipotoxicity.
2016·36citations·F. Les et al.·Chemico-biological interactions
Chemico-biological interactions
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition
The imidazoline compound RX871024 promotes insulinoma cell death independent of its action on AMPK, suggesting potential use in treating insulinomas.
2016·3citations·I. Zaitseva et al.·Investigational New Drugs
Investigational New Drugs
The imidazoline receptors and ligands in pain modulation
Imidazoline receptors and their ligands play a crucial role in pain modulation, making them potential new drug targets for analgesics and preventing opioid tolerance and addiction.
2015·17citations·N. Bektas et al.·Indian Journal of Pharmacology
Indian Journal of Pharmacology